Histidine

Histidine

SCHEMBL388560

N[C@@H](Cc1cnc[nH]1)C(=O)O.OO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 1.00
SLC7A5 Q01650 1/20 1.00
CPB2 Q96IY4 1/20 0.59
ALDH1A1 P00352 4/20 0.58
HRH4 Q9H3N8 3/20 0.58
HRH3 Q9Y5N1 3/20 0.58
NFKB1 P19838 2/20 0.58
MEN1 O00255 1/20 0.58
GLA P06280 1/20 0.58
KMT2A Q03164 1/20 0.58
CYP1A2 P05177 1/20 0.58
THPO P40225 1/20 0.58
LMNA P02545 1/20 0.56
APEX1 P27695 1/20 0.56
BLM P54132 1/20 0.56
GABRA1 P14867 1/20 0.55
TSHR P16473 1/20 0.55
GABRR1 P24046 1/20 0.55
GABRR2 P28476 1/20 0.55
GABRA5 P31644 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL28071764 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL30852263 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL3260 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL137600 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
D-Histidine SCHEMBL288043 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL19974306 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL25357958 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL25267810 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL6005501 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL25362582 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252333-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS Oxygen Biotherapeutics, Inc. (US) 2010-11-24 EP claimed
WO-2009102487-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS OXYGEN BIOTHERAPEUTICS, INC. (US) 2009-08-20 WO claimed
US-20150231177-A1 Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications VIRGINIA COMMONWEALTH UNIVERSITY (US) 2015-08-20 US disclosed
US-20130289471-A1 GAS BASED WOUND AND TISSUE THERAPEUTICS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2013-10-31 US disclosed
US-20120207793-A1 Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications VIRGINIA COMMONWEALTH UNIVERSITY 2012-08-16 US disclosed
US-20120184898-A1 GAS BASED WOUND AND TISSUE THERAPEUTICS TENAX THERAPEUTICS, INC 2012-07-19 US disclosed
US-8101117-B2 Controlled gas pore formers in extruded ware CORNING, INCORPORATED (US) 2012-01-24 US disclosed
EP-2252333-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS Oxygen Biotherapeutics, Inc. (US) 2010-11-24 EP disclosed
US-20090298667-A1 Controlled Gas Pore Formers in Extruded Ware CORNING INCORPORATED 2009-12-03 US disclosed
WO-2009102487-A2 GAS BASED WOUND AND TISSUE THERAPEUTICS OXYGEN BIOTHERAPEUTICS, INC. (US) 2009-08-20 WO disclosed
US-20090202617-A1 Gas based wound and tissue therapeutics TENAX THERAPEUTICS, INC 2009-08-13 US disclosed
US-20090169630-A1 Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications VIRGINIA COMMONWEALTH UNIVERSITY 2009-07-02 US disclosed
EP-2024287-A1 METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES Virginia Commonwealth University (US) 2009-02-18 EP disclosed
WO-2009006586-A2 SELF-CONTAINED OXYGEN GENERATING AND BREATHING SYSTEMS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2009-01-08 WO disclosed
WO-2007134304-A1 METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES VIRGINIA COMMONWEALTH UNIVERSITY (US) 2007-11-22 WO disclosed
EP-0409612-A1 Histidine-hydrogen peroxide adduct and process for preparing same TOKAI DENKA KOGYO KABUSHIKI KAISHA (JP) 1991-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090202617-A1 Gas based wound and tissue therapeutics PGF, FGF2, FGF1 CYP3A4 3801/4885SLC7A5 4142/4885CPB2 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.